In the two cases discussed, treatment with LNZ and MOX appeared successful, despite a lack of official recommendation for both drugs in treating children. Second-line drugs have a high risk of adverse effects, such as bone marrow suppression and peripheral/optic neuropathy, as well as cutaneous, gastrointestinal, central nervous system (CNS), cardiac, and musculoskeletal damage. In the cases presented, the guardians understood the need to proceed aggressively and gave approval to use the drugs. The children were carefully monitored for complications and treatment failure.